Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. A researcher at work in an AustinPx laboratory. (Image courtesy of AustinPx) Thermo Fisher’s Patheon division has signed an exclusive agreement with AustinPx to install the Texas CDMO’s KinetiSol technology at Patheon’s Bend, Oregon, and Cincinnati sites. AustinPx specializes in bioavailability enhancement for orally delivered small molecules, and the placement plugs into Patheon’s Quadrant 2 platform, which applies AI/ML to formulation prediction. It expands access to KinetiSol-enabled amorphous solid dispersion (ASD) work across development, scale-up, and commercial manufacturing. Some 40% of commercialized drugs…
Thermo Fisher’s Patheon division has signed an exclusive agreement with AustinPx to install the Texas CDMO’s KinetiSol technology at Patheon’s Bend, Oregon, and Cincinnati sites. AustinPx specializes in bioavailability enhancement for orally delivered small molecules, and the placement plugs into Patheon’s Quadrant 2 platform, which applies AI/ML to formulation prediction. It expands access to KinetiSol-enabled…
The post CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division appeared first on Drug Discovery and Development.
US Pharma Marketing